TransMedics Group (TMDX) Q3 Revenue Beat; Raises FY Revenue Guidance

TransMedics Group (NASDAQ: TMDX) reported Q3 EPS of ($0.78), $0.62 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $66.4 million versus the consensus estimate of $49.19 million.

GUIDANCE:

TransMedics Group sees FY2023 revenue of $222-230 million, versus prior of $180-$190 million and the consensus of $194.18 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• C.H. Robinson acquires DeSpir Logistics for $75 million
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target